SG11202109159VA - Methods of treating borderline personality disorder - Google Patents

Methods of treating borderline personality disorder

Info

Publication number
SG11202109159VA
SG11202109159VA SG11202109159VA SG11202109159VA SG 11202109159V A SG11202109159V A SG 11202109159VA SG 11202109159V A SG11202109159V A SG 11202109159VA SG 11202109159V A SG11202109159V A SG 11202109159VA
Authority
SG
Singapore
Prior art keywords
methods
personality disorder
borderline personality
treating
treating borderline
Prior art date
Application number
Inventor
Arjol Carlos Manuel Buesa
Roger Alan Bullock
Quiroga José Antonio Ramos
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of SG11202109159VA publication Critical patent/SG11202109159VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
SG11202109159V 2019-03-20 2020-03-20 Methods of treating borderline personality disorder SG11202109159VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382196 2019-03-20
PCT/EP2020/057803 WO2020188090A1 (en) 2019-03-20 2020-03-20 Methods of treating borderline personality disorder

Publications (1)

Publication Number Publication Date
SG11202109159VA true SG11202109159VA (en) 2021-10-28

Family

ID=65991740

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109159V SG11202109159VA (en) 2019-03-20 2020-03-20 Methods of treating borderline personality disorder

Country Status (12)

Country Link
US (1) US20220151998A1 (en)
EP (1) EP3941466A1 (en)
JP (1) JP2022525679A (en)
KR (1) KR20210141933A (en)
CN (1) CN113613653A (en)
AU (1) AU2020242302A1 (en)
BR (1) BR112021016064A2 (en)
CA (1) CA3130638A1 (en)
IL (1) IL286305A (en)
MX (1) MX2021011256A (en)
SG (1) SG11202109159VA (en)
WO (1) WO2020188090A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY197785A (en) 2016-03-15 2023-07-13 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US20070208082A1 (en) 2005-08-10 2007-09-06 John Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
US20110092601A1 (en) 2007-04-13 2011-04-21 The Johns Hopkins University Lysine-specific demethylase inhibitors
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
WO2010143582A1 (en) 2009-06-11 2010-12-16 公立大学法人名古屋市立大学 Phenylcyclopropylamine derivatives and lsd1 inhibitors
US9708255B2 (en) 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
CA2812683C (en) 2009-09-25 2017-10-10 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
BR112012026694A2 (en) 2010-04-19 2016-07-12 Oryzon Genomics Sa lysine 1-specific demethylase inhibitors and their use
EA022459B1 (en) 2010-04-20 2016-01-29 Университа' Дельи Студи Ди Рома "Ла Сапиенца" Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
SI2598482T1 (en) 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
SG193241A1 (en) 2011-03-25 2013-10-30 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
KR20140052018A (en) 2011-08-09 2014-05-02 다케다 야쿠힌 고교 가부시키가이샤 Cyclopropaneamine compound
JP6122006B2 (en) 2011-08-15 2017-04-26 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション Substituted (E) -N '-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
US9289415B2 (en) 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
BR112014009238B1 (en) 2011-10-20 2022-08-09 Oryzon Genomics S.A. (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS, THEIR USES AND PHARMACEUTICAL COMPOSITIONS
JP6215212B2 (en) 2011-10-20 2017-10-18 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． (Hetero) arylcyclopropylamine compounds as LSD1 inhibitors
US9751885B2 (en) 2012-10-12 2017-09-05 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
EP2927212A4 (en) 2012-11-28 2016-06-08 Univ Kyoto Lsd1-selective inhibitor having lysine structure
EP2925307B1 (en) 2012-11-30 2020-10-28 McCord, Darlene E. Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (en) 2013-01-18 2013-04-24 郑州大学 Application of amino dithio formic ester compound with triazolyl in preparing medicine taking LSD1 (Lysine Specificity Demethylase 1) as target
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
SG11201510376QA (en) 2013-06-19 2016-01-28 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
CN103319466B (en) 2013-07-04 2016-03-16 郑州大学 Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof
NZ716427A (en) 2013-08-06 2021-07-30 Imago Biosciences Inc Kdm1a inhibitors for the treatment of disease
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
US9556170B2 (en) 2013-08-30 2017-01-31 University Of Utah Research Foundation Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
WO2015089192A1 (en) 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
EP3102034A4 (en) 2014-02-07 2017-07-12 MUSC Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
EP3626713B1 (en) 2014-02-13 2021-09-29 Incyte Corporation Cyclopropylamines for use as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN106488915B (en) 2014-02-13 2020-10-02 因赛特公司 Cyclopropylamines as LSD1 inhibitors
EP3114109A4 (en) 2014-03-07 2017-10-18 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
CN103893163B (en) 2014-03-28 2016-02-03 中国药科大学 The application of 2-([1,1 '-biphenyl]-4-base) 2-oxoethyl 4-((the chloro-4-aminomethyl phenyl of 3-) is amino)-4-oxobutanoic acid esters in preparation LSD1 inhibitor medicaments
MY180575A (en) 2014-04-11 2020-12-02 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
CN103961340B (en) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 A kind of LSD1 inhibitor and its application
EP3137169B1 (en) 2014-05-01 2021-11-10 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
AU2015265820C1 (en) 2014-05-30 2020-01-16 Ieo - Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine compounds as histone demethylase inhibitors
CN104119280B (en) 2014-06-27 2016-03-16 郑州大学 Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application
WO2015200843A1 (en) 2014-06-27 2015-12-30 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
EP3164509B1 (en) 2014-07-03 2021-12-29 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP3511319B1 (en) 2014-07-03 2023-05-03 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
AU2015311805B2 (en) 2014-09-05 2020-04-02 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP3250552B1 (en) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016130952A1 (en) 2015-02-12 2016-08-18 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
CN106146361A (en) 2015-03-16 2016-11-23 四川大学 Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
CN106045862B (en) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 Cyclopropyl amine spiral shell (miscellaneous) cycle compound, its pharmaceutical composition and application
EP3286172B1 (en) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
WO2017004519A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
EA035534B1 (en) 2015-08-12 2020-06-30 Инсайт Корпорейшн Salts of an lsd1 inhibitor
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
CN108473442B (en) 2015-11-05 2022-03-25 赛尔基因昆蒂赛尔研究公司 Compositions comprising inhibitors of lysine-specific demethylase-1
CA3006434C (en) 2015-11-27 2021-03-16 Taiho Pharmaceutical Co., Ltd. Biphenyl compound or salt thereof
WO2017109061A1 (en) 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CA3009805C (en) 2015-12-29 2023-10-17 Mirati Therapeutics, Inc. Lsd1 inhibitors
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
US10590079B2 (en) 2016-03-01 2020-03-17 Novartis Ag Cyano-substituted indoles as LSD1 inhibitors
CN107200706A (en) 2016-03-16 2017-09-26 中国科学院上海药物研究所 Cyclopropylamine class compound of one class fluorine substitution and preparation method thereof, pharmaceutical composition and purposes
US20170283397A1 (en) 2016-03-31 2017-10-05 University Of Utah Research Foundation Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors
AU2017263361B2 (en) 2016-05-09 2021-08-05 Jubilant Epicore LLC Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN107513068A (en) 2016-06-16 2017-12-26 中国科学院上海药物研究所 A kind of new compound and its preparation and application with FGFR inhibitory activity
CN106478639B (en) 2016-09-05 2018-09-18 郑州大学 LSD1 inhibitor, preparation method and the application of 1,2,4-triazole of pyrimido
CN106432248B (en) 2016-09-27 2018-11-27 郑州大学 The LSD1 of triazole containing pyrimido inhibitor, preparation method and application
RS64889B1 (en) 2016-10-26 2023-12-29 Constellation Pharmaceuticals Inc Lsd1 inhibitors and medical uses thereof
WO2018081342A1 (en) 2016-10-26 2018-05-03 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
CN110248926B (en) 2017-01-24 2022-12-06 石药集团中奇制药技术（石家庄）有限公司 LSD1 inhibitor and preparation method and application thereof
CN106831489B (en) 2017-03-23 2018-04-17 郑州大学 Tranylcypromine acylhydrazone, preparation method and applications
CN106928235A (en) 2017-05-03 2017-07-07 郑州大学 The LSD1 of triazole containing pyrimido inhibitor, its preparation method and application
WO2018213211A1 (en) 2017-05-15 2018-11-22 The Regents Of The University Of Michigan Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
US11479563B2 (en) 2017-05-26 2022-10-25 Taiho Pharmaceutical Co., Ltd. Biphenyl compound or salt thereof
KR20180134675A (en) 2017-06-09 2018-12-19 한미약품 주식회사 Cyclopropylamine derivative compound and use thereof
UY37774A (en) 2017-06-19 2019-01-31 Novartis Ag SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME
JP2020152641A (en) 2017-07-07 2020-09-24 国立研究開発法人理化学研究所 Novel compound having lysine-specific demethylating enzyme 1 inhibitory activity, method for producing the same, and use of the same
JP2020529995A (en) * 2017-08-03 2020-10-15 オリゾン ジェノミックス ソシエダッド アノニマ How to treat behavioral changes

Also Published As

Publication number Publication date
AU2020242302A1 (en) 2021-09-16
WO2020188090A1 (en) 2020-09-24
KR20210141933A (en) 2021-11-23
CA3130638A1 (en) 2020-09-24
US20220151998A1 (en) 2022-05-19
IL286305A (en) 2021-10-31
MX2021011256A (en) 2021-10-01
BR112021016064A2 (en) 2021-10-05
CN113613653A (en) 2021-11-05
EP3941466A1 (en) 2022-01-26
JP2022525679A (en) 2022-05-18

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
SG11202010830WA (en) Methods of treating phenylketonuria
ZA201808258B (en) Methods of treating pancreatic cancer
EP3658153A4 (en) Methods of treating tumor metastasis
SG11202010793UA (en) Methods of treating cancer
EP3551189A4 (en) Method of treating epilepsy
EP4041312A4 (en) Methods of treating an eye disorder
ZA202203776B (en) Methods of treating epilepsy using the same
EP3969456A4 (en) Methods of treating a mk2-mediated disorder
IL278759A (en) Method of treating major depressive disorder
SG11202112232YA (en) Methods of treating neuropathy
SG11202107017TA (en) Methods of treating cancer
IL287210A (en) Method of treating tumours
IL287130A (en) Methods of treating pruritus
IL286305A (en) Methods of treating borderline personality disorder
IL281600A (en) Methods of treating cancer
IL277981A (en) Methods of treating cancer
IL289811A (en) Method of treating cancer
IL290213A (en) Methods of treating multifocal cancer
IL288353A (en) Methods of treating cholangiocarcinoma
IL286099A (en) Methods of treating disease with levoketoconazole
EP4072561A4 (en) Methods of treating cancer
EP3781264A4 (en) Methods of treating attention deficit hyperactivity disorder
EP3801547A4 (en) Methods of treating cancer
EP3541371A4 (en) Methods for treatment of interstitial cystitis